- Home
- NKTX vs MPA Comparison
NKTX vs MPA Comparison
Compare NKTX & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- MPA
- Stock Information
- Founded
- NKTX 2015
- MPA 1992
- Country
- NKTX United States
- MPA United States
- Employees
- NKTX N/A
- MPA N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- MPA Finance Companies
- Sector
- NKTX Health Care
- MPA Finance
- Exchange
- NKTX Nasdaq
- MPA Nasdaq
- Market Cap
- NKTX 123.5M
- MPA 139.0M
- IPO Year
- NKTX 2020
- MPA N/A
- Fundamental
- Price
- NKTX $2.12
- MPA $10.77
- Analyst Decision
- NKTX Strong Buy
- MPA
- Analyst Count
- NKTX 6
- MPA 0
- Target Price
- NKTX $14.40
- MPA N/A
- AVG Volume (30 Days)
- NKTX 578.6K
- MPA 25.2K
- Earning Date
- NKTX 08-12-2025
- MPA 01-01-0001
- Dividend Yield
- NKTX N/A
- MPA 3.83%
- EPS Growth
- NKTX N/A
- MPA N/A
- EPS
- NKTX N/A
- MPA N/A
- Revenue
- NKTX N/A
- MPA N/A
- Revenue This Year
- NKTX N/A
- MPA N/A
- Revenue Next Year
- NKTX N/A
- MPA N/A
- P/E Ratio
- NKTX N/A
- MPA N/A
- Revenue Growth
- NKTX N/A
- MPA N/A
- 52 Week Low
- NKTX $1.31
- MPA $9.87
- 52 Week High
- NKTX $6.66
- MPA $12.21
- Technical
- Relative Strength Index (RSI)
- NKTX 57.92
- MPA 58.65
- Support Level
- NKTX $1.74
- MPA $10.50
- Resistance Level
- NKTX $2.32
- MPA $10.67
- Average True Range (ATR)
- NKTX 0.15
- MPA 0.09
- MACD
- NKTX 0.02
- MPA 0.02
- Stochastic Oscillator
- NKTX 62.96
- MPA 96.43
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.